2,6-dimethylphenyl isopropyl ether | 54350-31-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2,6-dimethylphenyl isopropyl ether
• 英文别名: Benzene, 1,3-dimethyl-2-(1-methylethoxy)-；1,3-dimethyl-2-propan-2-yloxybenzene
• CAS: 54350-31-1
• 化学式: C₁₁H₁₆O
• 分子量: 164.247
• InChiKey: VSZHMZHUNQBLCO-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,6-dimethylphenyl isopropyl ether 以70%的产率得到
  参考文献：
  名称：

  MCLAUGHLIN M. P.; CREEDON V.; MILLER B., TETRAHEDRON LETT., 1978, NO 38, 3537-3540

  摘要：

  DOI：
• 作为产物：
  描述：

  2,6-二甲基苯酚 、 2-溴丙烷 在 potassium carbonate 作用下， 生成 2,6-dimethylphenyl isopropyl ether
  参考文献：
  名称：

  Meta substitution in electrophilic benzylations of 2,6-dimethylphenol and alkyl 2,6-dimethylphenyl ethers: product distributions and mechanism

  摘要：

  DOI：

  10.1021/jo00343a022

文献信息

• FUSED IMIDAZOLE DERIVATIVE HAVING TTK INHIBITORY ACTION
  申请人：Kusakabe Ken-ichi

  公开号：US20120059162A1

  公开（公告）日：2012-03-08

  Provided are a compound represented by general formula (1) and having a TTK inhibitory action and a medicine containing the compound. In formula (1), (X, Y, V, W) is (—N═, ═CR 1 —, ═N—, —CR 7 ═), (—CR 2 ═, ═N—, ═N—, —CR 7 ═), etc.; A is an (un)substituted aromatic hydrocarbon ring, etc.; L is a single bond, —C(═O)—NR A —, etc.; Z is a group represented by the formula —NR 3 R 4 or a group represented by the formula —OR 5 ; R 1 to R 3 , R 6 , and R 7 each is a hydrogen atom, etc.; R 4 and R 5 each is an (un)substituted alkyl, etc.; and R 8 is an (un)substituted cycloalkyl, etc.

  提供了一个由一般式（1）表示的化合物，具有TTK抑制作用，以及含有该化合物的药物。在式（1）中，（X，Y，V，W）为（—N═，═CR1—，═N—，—CR7═），（—CR2═，═N—，═N—，—CR7═），等等；A为（非）取代芳香烃环等；L为一个单键，—C(═O)—NRA—等；Z为由式—NR3R4或式—OR5表示的基团；R1至R3，R6和R7分别是氢原子等；R4和R5分别是（非）取代烷基等；R8是（非）取代环烷基等。
• PROSTACYCLIN DERIVATIVES
  申请人：Masse Craig E.

  公开号：US20120270934A1

  公开（公告）日：2012-10-25

  This invention relates to novel prostacyclin derivatives and acceptable salts thereof. The invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions beneficially treated by prostacyclin, and in particular those diseases and conditions beneficially treated by dilators of systemic and pulmonary arterial vascular beds or by platelet aggregation inhibitors.

  本发明涉及新颖的前列环素衍生物及其可接受的盐。本发明还提供了包含本发明化合物的组合物，并使用这些组合物在治疗利于前列环素治疗的疾病和病况的方法中，特别是那些通过扩张系统和肺动脉血管床或通过抑制血小板聚集而有益地治疗的疾病和病况。
• PRODRUGS OF OXAZOLIDINONE CETP INHIBITORS
  申请人：Mills Sander G.

  公开号：US20110218177A1

  公开（公告）日：2011-09-08

  The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient.

  公式I的化合物是具有中心噁唑烷环的CETP抑制剂前药。这些化合物在给患者使用后通过HX的消除环化形成噁唑烷环。
• HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS
  申请人：Hadida-Ruah Sara Sabina

  公开号：US20110306607A1

  公开（公告）日：2011-12-15

  The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及杂环色烯-螺环哌啶酰胺类化合物，其可用作离子通道抑制剂。本发明还提供了包含本发明化合物的药学上可接受的组合物，并提供了使用这些组合物治疗各种疾病的方法。
• Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels
  申请人：HADIDA-RUAH Sara Sabina

  公开号：US20140171427A1

  公开（公告）日：2014-06-19

  The invention relates to heterocyclic chromene-spirocyclic piperidine amides useful as inhibitors of ion channels. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods of using the compositions in the treatment of various disorders.

  本发明涉及杂环色烯-螺环哌啶酰胺，其可用作离子通道抑制剂。本发明还提供了包含该发明化合物的药学上可接受的组合物以及使用该组合物治疗各种疾病的方法。